174 related articles for article (PubMed ID: 36775953)
1. Papillary Intralymphatic Angioendothelioma in a Child With
Debelenko L; Mansukhani MM; Remotti F
Pediatr Dev Pathol; 2023; 26(2):166-171. PubMed ID: 36775953
[TBL] [Abstract][Full Text] [Related]
2. Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum.
Chen H; Gao W; Liu H; Sun B; Hua C; Lin X
Ann Plast Surg; 2023 May; 90(5S Suppl 2):S209-S215. PubMed ID: 36729078
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA-related overgrowth spectrum (PROS): new insight in known diseases.
Iriarte Fuster A; Cerdà Serra P; Riera-Mestre A
Med Clin (Barc); 2021 Nov; 157(10):483-488. PubMed ID: 34281706
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum: A brief report.
Denorme P; Morren MA; Hollants S; Spaepen M; Suaer K; Zutterman N; Labarque V; Legius E; Brems H
Pediatr Dermatol; 2018 May; 35(3):e186-e188. PubMed ID: 29493003
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
7. [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q; Canaud G
Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
9. Complex vascular anomalies and tissue overgrowth of limbs associated with increased skin temperature and peripheral venous dilatation: parks weber syndrome or PROS?
Su LX; Sun Y; Wang Z; Wang D; Yang X; Zheng L; Wen M; Fan X; Cai R
Hereditas; 2022 Jan; 159(1):1. PubMed ID: 34980271
[TBL] [Abstract][Full Text] [Related]
10. Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants.
Mussa A; Leoni C; Iacoviello M; Carli D; Ranieri C; Pantaleo A; Buonuomo PS; Bagnulo R; Ferrero GB; Bartuli A; Melis D; Maitz S; Loconte DC; Turchiano A; Piglionica M; De Luisi A; Susca FC; Bukvic N; Forleo C; Selicorni A; Zampino G; Onesimo R; Cappuccio G; Garavelli L; Novelli C; Memo L; Morando C; Della Monica M; Accadia M; Capurso M; Piscopo C; Cereda A; Di Giacomo MC; Saletti V; Spinelli AM; Lastella P; Tenconi R; Dvorakova V; Irvine AD; Resta N
J Med Genet; 2023 Feb; 60(2):163-173. PubMed ID: 35256403
[TBL] [Abstract][Full Text] [Related]
11. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
[TBL] [Abstract][Full Text] [Related]
12. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
[TBL] [Abstract][Full Text] [Related]
13. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of 13 patients with PIK3CA-related overgrowth spectrum using a targeted deep sequencing approach.
de Kock L; Cuillerier A; Gillespie M; Couse M; Hartley T; Mears W; Bernier FP; Chudley AE; Frosk P; Nikkel SM; Innes AM; Lauzon J; Thomas M; Guerin A; Armour CM; Weksberg R; Scott JN; Watkins D; Harvey S; Cytrynbaum C; ; Kernohan KD; Boycott KM
Am J Med Genet A; 2024 Mar; 194(3):e63466. PubMed ID: 37949664
[TBL] [Abstract][Full Text] [Related]
15. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA-related overgrowth with an uncommon phenotype: case report.
Rotunno R; Diociaiuti A; Pisaneschi E; Carnevale C; Dentici M; El Hachem M
Ital J Pediatr; 2022 May; 48(1):71. PubMed ID: 35551640
[TBL] [Abstract][Full Text] [Related]
17. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
18. Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum.
Yeung KS; Ip JJ; Chow CP; Kuong EY; Tam PK; Chan GC; Chung BH
Am J Med Genet A; 2017 Apr; 173(4):978-984. PubMed ID: 28328134
[TBL] [Abstract][Full Text] [Related]
19. Cerebrofacial vascular metameric syndrome is caused by somatic pathogenic variants in
Sheppard SE; Sanders VR; Srinivasan A; Finn LS; Adams D; Elton A; Amlie-Lefond C; Nelson Z; Dmyterko V; Jensen D; Zenner K; Perkins J; Bennett JT
Cold Spring Harb Mol Case Stud; 2021 Dec; 7(6):. PubMed ID: 34887309
[TBL] [Abstract][Full Text] [Related]
20. Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities.
Tian W; Sun L; Zhang Q; Zhao J; Guo Y; Zhong W; Liu L; Meirelles K; Tang S; Zhang J; Huang Y; Yin Y; Zhang N; Zhao Z; Li Q; Wu N; Fang P; Chang F; Wu Z
Mol Genet Genomics; 2022 Mar; 297(2):387-396. PubMed ID: 35122151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
